MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
Press release content from Accesswire. The AP news staff was not involved in its creation. MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab January 12, 2021 GMT PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that Health Canada has accepted the New Drug Submission (NDS) for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by ta...
Source: apnews.com